Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene TP53
Variant inact mut
Impact List unknown
Protein Effect loss of function
Gene Variant Descriptions TP53 inact mut indicates that this variant results in a loss of function of the Tp53 protein. However, the specific amino acid change has not been identified.
Associated Drug Resistance
Category Variants Paths

TP53 mutant TP53 inact mut

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03144804 Phase II Lamivudine A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer Completed USA 0
NCT03654716 Phase I ALRN-6924 + Cytarabine ALRN-6924 Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer Completed USA 0
NCT04778397 Phase III Cytarabine + Idarubicin Azacitidine + Venetoclax Azacitidine + Hu5F9-G4 Cytarabine + Daunorubicin Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated (ENHANCE-2) Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 5
NCT01097278 Phase 0 Cholecalciferol S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Completed USA 0
NCT05605509 Phase II Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 RP-6306 in Patients With Advanced Cancer Recruiting CAN 0
NCT05338346 Phase I ATG-018 A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (ATRIUM) Recruiting AUS 0
NCT06212583 Phase II Abiraterone + Niraparib High-Risk Metachronous Oligometastatic Prostate Cancer Trial (KNIGHTS) Recruiting USA 0
NCT05932667 Phase II Fulvestrant + Milademetan Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer (DEMETER) Terminated FRA 0
NCT04155840 Phase II Bendamustine + Copanlisib + Rituximab Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Terminated USA 0
NCT04049539 Phase II CPX-351 Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction Recruiting USA 0